MTS: Top 5 Stock Movers - HUDI, SNTG, RYAM, ARAV, & MMAT Stocks rallied this past Friday and yet still finished the week lower amid a cloudy outlook about what the latest payroll numbers mean for future rate hikes. The Dow climbed 1.26% to close at 32,403.22. The S&P 500 grew 1.36% settling at 3,770.55 and Nasdaq rose 1.28% closing at 10,475.25. Despite these gains the averages capped off the week with losses. Hawkish comments from Fed Chairman Jerome Powell on Wednesday increased worries that the central bank could keep boosting interest rates for longer than previously expected and put further pressure on stocks. Fed officials on Friday echoed Powell’s comments about potentially decreasing the size of rate hikes but needing to continue to raise rates for a longer period of time and potentially above the 4.6 percent level the central bank penciled in at its September meeting. In light of this news, which stocks had the most growth? Let’s find out in today’s episode of Money Talk Sundayz. Subscribe: https://linktr.ee/moneytalksundayz Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping. Coming in at the number 4 spot is Aravive, Inc. Ticker symbol ARAV, Aravive had a one-week-change of 66.36% closing trading at 1.81. ARAV is a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. Rounding out the top 5 is a goodie from last year and you’ve probably seen in the intro, Meta Materials. Ticker symbol MMAT, Meta had a one-week-change of 63.11% closing trading Friday at 1.62. For those that don’t know, MMAT invents, designs, develops, and manufactures various functional materials and nanocomposites. Its products include metaAIR, a laser glare protection eyewear; NANOWEB, a transparent conductive film; holoOPTIX, a holographic optical element; glucoWISE, a non-invasive glucose measurement device; and metaSURFACE, which allows an enhancement in signal to noise ratio of up to 40 times for magnetic resonance imaging scans. MMAT is up over 120% this month following an MOU and purchase order with DuPont Teijin Films and Mitsubishi Electric Europe worth $4.3 million. The partnerships seeks to improve traditional lithium-ion batteries by reducing their dependence on copper. Meta will utilize its PLASMAfusion technology, which adds thin layers of copper on the sides of a polyester substrate. This can reduce the weight of the current collector by up to 80%, which increases energy density and battery life. DuPont will supply the polyester substrates, while Mitsubishi will contribute automation technology and interface to machine builders. The batteries created in this process can be used for electric vehicles (EVs) and other purposes. Are you invested in any of these stocks? If so, when did you jump in and what prompted you to buy into that stock? I’m curious as to how certain signals get out. What I really want to know… with so many different stocks out there, how do you really know which ones are getting ready to pop… especially if you’ve never heard of the stock before? I need a program to scan the whole market and pick up triggers and alert me. Alas I’m your boy Stevie Bee signing off for Money Talk Sundayz.